SG11202103133QA - Pyrazole derivatives as h4 antagonist compounds - Google Patents
Pyrazole derivatives as h4 antagonist compoundsInfo
- Publication number
- SG11202103133QA SG11202103133QA SG11202103133QA SG11202103133QA SG11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazole derivatives
- antagonist compounds
- antagonist
- compounds
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1817047.2A GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
| PCT/GB2019/052997 WO2020079457A1 (fr) | 2018-10-19 | 2019-10-21 | Dérivés de pyrazole en tant que composés antagonistes de h4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103133QA true SG11202103133QA (en) | 2021-05-28 |
Family
ID=64453795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103133QA SG11202103133QA (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210300906A1 (fr) |
| EP (1) | EP3867248A1 (fr) |
| JP (1) | JP2022507013A (fr) |
| KR (1) | KR20210079318A (fr) |
| CN (1) | CN113272297B (fr) |
| AU (1) | AU2019360428B2 (fr) |
| BR (1) | BR112021007372A2 (fr) |
| CA (1) | CA3116628A1 (fr) |
| GB (1) | GB201817047D0 (fr) |
| MX (1) | MX2021004280A (fr) |
| SG (1) | SG11202103133QA (fr) |
| WO (1) | WO2020079457A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005858D0 (en) * | 2020-04-22 | 2020-06-03 | Heptares Therapeutics Ltd | H4 Antagonist compounds |
| KR102655210B1 (ko) * | 2021-03-26 | 2024-04-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
| CN118076587A (zh) * | 2021-10-19 | 2024-05-24 | 优迈特株式会社 | 含氟吡唑化合物及其制造方法 |
| KR102621694B1 (ko) * | 2022-09-15 | 2024-01-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000005230A1 (fr) * | 1998-07-24 | 2000-02-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de pyrazole et sels correspondants |
| WO2005054239A1 (fr) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | Derives de 2-aminopyrimidine |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| AR074199A1 (es) * | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
-
2018
- 2018-10-19 GB GBGB1817047.2A patent/GB201817047D0/en not_active Ceased
-
2019
- 2019-10-21 KR KR1020217014805A patent/KR20210079318A/ko unknown
- 2019-10-21 CA CA3116628A patent/CA3116628A1/fr active Pending
- 2019-10-21 JP JP2021521390A patent/JP2022507013A/ja active Pending
- 2019-10-21 AU AU2019360428A patent/AU2019360428B2/en active Active
- 2019-10-21 CN CN201980084053.7A patent/CN113272297B/zh active Active
- 2019-10-21 MX MX2021004280A patent/MX2021004280A/es unknown
- 2019-10-21 US US17/285,776 patent/US20210300906A1/en active Pending
- 2019-10-21 WO PCT/GB2019/052997 patent/WO2020079457A1/fr active Application Filing
- 2019-10-21 BR BR112021007372-8A patent/BR112021007372A2/pt unknown
- 2019-10-21 SG SG11202103133QA patent/SG11202103133QA/en unknown
- 2019-10-21 EP EP19794235.2A patent/EP3867248A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201817047D0 (en) | 2018-12-05 |
| AU2019360428A1 (en) | 2021-04-29 |
| CA3116628A1 (fr) | 2020-04-23 |
| US20210300906A1 (en) | 2021-09-30 |
| WO2020079457A1 (fr) | 2020-04-23 |
| JP2022507013A (ja) | 2022-01-18 |
| EP3867248A1 (fr) | 2021-08-25 |
| KR20210079318A (ko) | 2021-06-29 |
| MX2021004280A (es) | 2021-05-31 |
| AU2019360428B2 (en) | 2024-05-09 |
| CN113272297B (zh) | 2024-03-19 |
| BR112021007372A2 (pt) | 2021-07-20 |
| CN113272297A (zh) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
| SG11202103133QA (en) | Pyrazole derivatives as h4 antagonist compounds | |
| IL283990A (en) | Modified oxopyridine derivatives | |
| ZA202204675B (en) | New methylquinazolinone derivatives | |
| IL279453B (en) | Pyrazole history as malt1 inhibitors | |
| EP3331532A4 (fr) | Composés d'aminoquinazoline substitués en tant qu'antagonistes d'a2a | |
| IL289197A (en) | History of 2-hydroxycycloalkane-1-carbamoyl | |
| ZA201708611B (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof | |
| IL279452B (en) | Pyrazole history as malt1 inhibitors | |
| IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
| IL279938A (en) | History of spirochroman | |
| ZA202106024B (en) | Heterocyclic derivatives | |
| IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
| IL290815A (en) | History of alpha-d-galactopyranoside | |
| IL268565B (en) | A history of pyrazoles as bromodomain inhibitors | |
| HUE064831T2 (hu) | Szulfonil-amino-benzamid származékok | |
| EP3327004A4 (fr) | Composé hétérocyclique contenant de l'azote | |
| ZA201904313B (en) | Heterocyclic derivatives as antibacterial compounds | |
| HUE062256T2 (hu) | Dihidrokromén-származékok | |
| GB201919213D0 (en) | Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds | |
| GB201918392D0 (en) | H4 Antagonist compounds | |
| GB201901868D0 (en) | H4 antagonist compounds | |
| IL310777A (en) | The history of S-alanine is altered | |
| GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| GB201910865D0 (en) | Antagonist compounds |